Delivery Order SPE2DB20D3303-SPE2DB25FA3ZT
- Not listed
- The Defense Logistics Agency awarded a $2,194.02 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a firm fixed price, non-set-aside contract performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX),...
- The Defense Logistics Agency awarded a $7,046.76 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Monovisc 88 mg/4 ml syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a $38,034.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract, which is not set-aside and was competitively awarded, requires completion by June 18, 2025, with performance to be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,096.73 to AmerisourceBergen Drug Corp for the supply of MONOVISC 88 MG/4 ML syringes (4 ML quantity) on August 12, 2025, with a completion date of August 13, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate...
- The Defense Logistics Agency awarded a $8,057.84 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on September 23, 2025, with completion expected by September 24, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a $3,614.94 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion by June 2, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This...
- The Defense Logistics Agency awarded a $8,222.46 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 15, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $8,866.94 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes on August 25, 2025, with a completion date of August 26, 2025. This contract represents a firm fixed price delivery order with no set-aside designation, executed through competitive procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. Monovisc is...
- The Defense Logistics Agency awarded a delivery order valued at $6,708.32 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes on July 24, 2025, with completion expected by July 25, 2025. This firm fixed price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $2,409.96 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 ml syringes on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's larger indefinite delivery vehicle with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3ZTDelivery Order
The Defense Logistics Agency awarded a $1,204.98 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This is a non-set-aside contract with an ultimate completion date of September 23, 2025, and performance to be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive pharmaceutical supply agreement supporting military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, maintains an extensive portfolio of federal contracts with the Defense Logistics Agency covering diverse pharmaceutical products and medical supplies. The company's demonstrated capability to meet federal procurement requirements through open competition is evidenced by its consistent receipt of competitively awarded, non-set-aside contracts ranging from minimal-value transactions to substantial orders. This specific delivery order for Monovisc—an injectable viscosupplement used in orthopedic and joint care applications—exemplifies the company's role in supplying specialized medical commodities to support Defense Health Agency and military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/22/25 |